WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of Peter J. Langecker, M.D., Ph.D., as Executive Vice President and Chief Development Officer. Dr. Langecker will oversee the development of OXiGENE's drug candidates, ZYBRESTAT(tm) for oncology, ZYBRESTAT for ophthalmology, and OXi4503. Dr. Langecker is scheduled to begin his position with OXiGENE on June 29, 2009.
